Additional mechanisms involved in the anti-tumor effects of BDNF-AS include epigenetic suppression of GSK-3β expression in colorectal cells [62], targeting of miR-214 and EMT in esophageal cancer cells [63], stabilization of BDNF-AS in glioma cells by PABPC1 and STAU1-mediated decay [46], and stabilization of p53 in glioma cells via a positive feedback loop of BDNF-AS-ADAR-p53 [64]. The gene discussed is TP53; the disease is neoplasm.